 |
|
Effects of Continuing or Stopping Alendronate After 5 Years of Treatment
The Fracture Intervention Trial Long-term Extension (FLEX): A Randomized Trial
Dennis M. Black, PhD;
Ann V. Schwartz, PhD;
Kristine E. Ensrud, MD, MPH;
Jane A. Cauley, DrPH;
Silvina Levis, MD;
Sara A. Quandt, PhD;
Suzanne Satterfield, MD;
Robert B. Wallace, MD;
Douglas C. Bauer, MD, MPH;
Lisa Palermo, MA;
Lois E. Wehren, MD;
Antonio Lombardi, MD;
Arthur C. Santora, MD;
Steven R. Cummings, MD; for the FLEX Research Group
JAMA. 2006;296:2927-2938.
Context The optimal duration of treatment of women with postmenopausal osteoporosis is uncertain.
Objective To compare the effects of discontinuing alendronate treatment after 5 years vs continuing for 10 years.
Design and Setting Randomized, double-blind trial conducted at 10 US clinical centers that participated in the Fracture Intervention Trial (FIT).
Participants One thousand ninety-nine postmenopausal women who had been randomized to alendronate in FIT, with a mean of 5 years of prior alendronate treatment.
Intervention Randomization to alendronate, 5 mg/d (n = 329) or 10 mg/d (n = 333), or placebo (n = 437) for 5 years (1998-2003).
Main Outcome Measures The primary outcome measure was total hip bone mineral density (BMD); secondary measures were BMD at other sites and biochemical markers of bone remodeling. An exploratory outcome measure was fracture incidence.
Results Compared with continuing alendronate, switching to placebo for 5 years resulted in declines in BMD at the total hip (–2.4%; 95% confidence interval [CI], –2.9% to –1.8%; P<.001) and spine (–3.7%; 95% CI, –4.5% to –3.0%; P<.001), but mean levels remained at or above pretreatment levels 10 years earlier. Similarly, those discontinuing alendronate had increased serum markers of bone turnover compared with continuing alendronate: 55.6% (P<.001) for C-telopeptide of type 1 collagen, 59.5% (P < .001) for serum N = propeptide of type 1 collagen, and 28.1% (P<.001) for bone-specific alkaline phosphatase, but after 5 years without therapy, bone marker levels remained somewhat below pretreatment levels 10 years earlier. After 5 years, the cumulative risk of nonvertebral fractures (RR, 1.00; 95% CI, 0.76-1.32) was not significantly different between those continuing (19%) and discontinuing (18.9%) alendronate. Among those who continued, there was a significantly lower risk of clinically recognized vertebral fractures (5.3% for placebo and 2.4% for alendronate; RR, 0.45; 95% CI, 0.24-0.85) but no significant reduction in morphometric vertebral fractures (11.3% for placebo and 9.8% for alendronate; RR, 0.86; 95% CI, 0.60-1.22). A small sample of 18 transilial bone biopsies did not show any qualitative abnormalities, with bone turnover (double labeling) seen in all specimens.
Conclusions Women who discontinued alendronate after 5 years showed a moderate decline in BMD and a gradual rise in biochemical markers but no higher fracture risk other than for clinical vertebral fractures compared with those who continued alendronate. These results suggest that for many women, discontinuation of alendronate for up to 5 years does not appear to significantly increase fracture risk. However, women at very high risk of clinical vertebral fractures may benefit by continuing beyond 5 years.
Trial Registration clinicaltrials.gov Identifier: NCT 00398931
Author Affiliations: San Francisco Coordinating Center (Drs Black, Schwartz, Bauer, and Cummings and Ms Palermo), Departments of Epidemiology and Biostatistics (Drs Black and Schwartz and Ms Palermo) and Medicine (Dr Bauer), University of California, San Francisco, and California Pacific Medical Center Research Institute (Dr Cummings), San Francisco; Department of Medicine, VA Medical Center, Minneapolis, Minn (Dr Ensrud); Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pa (Dr Cauley); Department of Medicine, University of Miami, Miami, Fla (Dr Levis); School of Medicine, Wake Forest University, Winston-Salem, NC (Dr Quandt); Department of Preventive Medicine, University of Tennessee, Memphis (Dr Satterfield); College of Medicine, University of Iowa, Iowa City (Dr Wallace); and Merck Research Laboratories, Rahway, NJ (Drs Wehren, Lombardi, and Santora).
RELATED LETTERS
Use of Alendronate After 5 Years of Treatment
Juan Erviti and Javier Gorricho
JAMA. 2007;297(18):1979.
EXTRACT
| FULL TEXT
Use of Alendronate After 5 Years of Treatment
Susan M. Ott
JAMA. 2007;297(18):1979.
EXTRACT
| FULL TEXT
Use of Alendronate After 5 Years of Treatment
Pierre D. Delmas
JAMA. 2007;297(18):1979-1980.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Ten vs Five Years of Bisphosphonate Treatment for Postmenopausal Osteoporosis: Enough of a Good Thing
Cathleen S. Colón-Emeric
JAMA. 2006;296(24):2968-2969.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Severely Suppressed Bone Turnover and Atypical Skeletal Fragility
Visekruna et al.
J. Clin. Endocrinol. Metab. 2008;93:2948-2952.
ABSTRACT
| FULL TEXT
Update on the treatment of post-menopausal osteoporosis
Cole et al.
Br Med Bull 2008;86:129-143.
ABSTRACT
| FULL TEXT
Relative Effectiveness of Osteoporosis Drugs for Preventing Nonvertebral Fracture
Cadarette et al.
ANN INTERN MED 2008;148:637-646.
ABSTRACT
| FULL TEXT
Osteoporosis and Its Implications for Dental Patients
Edwards and Migliorati
Journal of the American Dental Association 2008;139:545-552.
ABSTRACT
| FULL TEXT
Should We Be Concerned About Jaw Osteonecrosis with Oral Bisphosphonates?
JWatch General 2008;2008:1-1.
FULL TEXT
Closing in on the Puzzle of ONJ
Glick
Journal of the American Dental Association 2008;139:12-15.
FULL TEXT
Osteonecrosis of the Jaws and Bisphosphonate Therapy
Ruggiero and Drew
J. Dent. Res. 2007;86:1013-1021.
ABSTRACT
| FULL TEXT
Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates
Kimmel
J. Dent. Res. 2007;86:1022-1033.
ABSTRACT
| FULL TEXT
What's New in Orthopaedic Trauma
Cole et al.
JBJS 2007;89:2560-2577.
FULL TEXT
Update in Endocrinology
Schlechte
ANN INTERN MED 2007;147:563-572.
FULL TEXT
Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic Acid
Brown et al.
Clin. Cancer Res. 2007;13:5406-5410.
ABSTRACT
| FULL TEXT
Cost-effectiveness of Bone Densitometry Followed by Treatment of Osteoporosis in Older Men
Schousboe et al.
JAMA 2007;298:629-637.
ABSTRACT
| FULL TEXT
Bisphosphonates and osteonecrosis of the jaw
Shenker and Jawad
Rheumatology (Oxford) 2007;46:1049-1051.
FULL TEXT
Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women
Baillie
Evid. Based Med. 2007;12:70-70.
FULL TEXT
Use of Alendronate After 5 Years of Treatment
Erviti and Gorricho
JAMA 2007;297:1979-1979.
FULL TEXT
Use of Alendronate After 5 Years of Treatment
Ott
JAMA 2007;297:1979-1979.
FULL TEXT
Use of Alendronate After 5 Years of Treatment
Delmas
JAMA 2007;297:1979-1980.
FULL TEXT
Update in Osteoporosis and Metabolic Bone Disorders
Shoback
J. Clin. Endocrinol. Metab. 2007;92:747-753.
ABSTRACT
| FULL TEXT
Five Years of Fosamax: Enough of a Good Thing?
JWatch Women's Health 2007;2007:2-2.
FULL TEXT
Bisphosphonate Therapy: To Stop or Not to Stop?
McClung
IBMS BoneKEy 2007;4:78-82.
FULL TEXT
How Long to Take Alendronate for Osteoporosis?
JWatch General 2007;2007:1-1.
FULL TEXT
Ten vs Five Years of Bisphosphonate Treatment for Postmenopausal Osteoporosis: Enough of a Good Thing
Colon-Emeric
JAMA 2006;296:2968-2969.
FULL TEXT
|
